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Abstract: 
Different dextran esters with various degrees of substitution (1, 2 and 3) were 
synthesized by esterification reaction, with three acid anhydrides: acetic 
anhydride, propionic anhydride, and butyric anhydride, separately. These 
modified polysaccharides were characterized by FT-IR, 1H NMR and 13C 
NMR spectroscopies. Enzymatic degradation of biopolymers by dextranase 
was also studied. The polymers showing the best degradation profiles were 
chosen to design blended free films in combination with a polymethacrylate 
(Eudragit® RS 30D) as a sustained release system for targeting to the colon. 
These free films were evaluated by permeability of theophylline used as 
tracer in different in vitro media of the gastro intestinal tract, in presence or in 
absence of dextranase. From these studies, it was concluded that dextran 
esters having the lower degree of substitution and constituted of short 
carbohydrate chains showed the best and significant enzymatic degradation 
and could be used as a promising carrier for specific colon drug delivery 
system. 
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Introduction  
The oral route is the most common and convenient of 
the existing administration methods for systemic drug 
delivery. It affords high patient acceptability, 
compliance, and ease of administration. Moreover, the 
cost of oral therapy is generally much lower than that 
of parenteral therapy [1,2]. Research interest in the area 
of colonic drug delivery has been fuelled by the need to 
better treat pathologies of the colon that range in 
seriousness from constipation and diarrhoea to 
debilitating   inflammatory  bowel  diseases,  ulcerative  
 
 
colitis and Crohn’s disease, through to colon 
carcinoma. Targeted oral drug delivery to the colon 
would therefore ensure a direct treatment at the disease 
site, lower dosing and a reduction of systemic side 
effects. Aside from local treatment, the colon can also 
be utilised as a portal for the entry of drugs into the 
bloodstream for the purpose of systemic therapy. For 
example, molecules that are degraded and/or poorly 
absorbed in the upper gut, such as peptides and 
proteins, may be better absorbed  from the more benign  
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environment of the colon. In addition, systemic 
absorption from the colon can also be used as a means 
of achieving chronotherapy for diseases that are 
sensitive to circadian rhythms such as asthma, angina, 
and arthritis [3,4]. 
Amongst the different strategies to reach the colon 
described in the literature [5], the simplest and less 
costly strategy consists using polyacrylate derivatives 
or polysaccharide-polyacrylate derivatives such as 
ammonio methacrylate copolymer. They can be a good 
choice for people suffering of colon disease for which 
any variability of pH into the colon occurs. Besides 
these synthetic polymers, the use of polysaccharides 
degradable by enzymes and/or bacteria present into the 
colon can also be a good strategy. Furthermore, 
polysaccharides are found in abundance, have wide 
availability, are inexpensive and available in a variety 
of structures with a variety of properties. They can be 
easily modified chemically and biochemically and are 
highly stable, safe, nontoxic, hydrophilic and gel 
forming and in addition biodegradable, which suggests 
their use in targeted drug delivery systems [6]. 
Furthermore, many of the polysaccharide-based 
delivery systems shield the drug from the hostile 
environments of the upper GIT [7,8]. 
Dextrans are a class of polysaccharides consisting of α-
1, 3 and α-1, 6 glycosidic linkages and having unique 
properties, such as biodegradability at specific body 
sites, e.g. the colon. Dextranases are the enzymes 
which hydrolyse these glycosidic linkages. Dextranase 
activities on the colon are shown by anaerobic gram-
negative intestinal bacteria especially the Bacteroides. 
The Bacteroides are the numerically predominant 
anaerobes in the colonic region of humans. They 
number about 1011 per gram of intestinal contents and 
constitute approximately 30% of total cultivable gut 
flora. The majority of strictly anaerobic bacteria in the 
colon are saccharolytic. The bacteria drive their energy 
from the fermentation of carbohydrates, which results 
in the production of short chain fatty acids [9]. 
Dextranase activity in human caecostomy effluent 
samples was reported to be 650 DU/ml, equivalent to 
30 U/ml measured in conventional enzyme units, and 
15 DU/g equivalent to 0.69 U/g in human fecal samples 
[10]. Due to its degradability in the colon, dextran is an 
ideal candidate for oral drug delivery systems. 
However, dextran itself cannot be used as drug carrier 
due to its high water solubility and therefore the first 
need is to make it more hydrophobic [11]. 
The aims of this study were to synthesize and 
characterize new dextran esters such as dextran acetate 
(Dex.Ace), dextran propionate (Dex.Pro) and dextran 
butyrate (Dex.But) with three degrees of substitution 
by esterification reaction, to be used as coatings or as a 
matrix systems for solid oral drug dosage forms 
(tablets, capsules and mini granules) in both cases as 
carriers for site specific drug delivery to the colon. 
Preparation of biodegradable matrix films consisted of 
dextran esters, as biodegradable modified 
polysaccharides into the colon, and Eudragit RL 30 D 
as a sustained-release polymer [12]. The permeability of 
those free films mixtures into different media 
mimicking the gastrointestinal tract was also realized. 
 
Materials and methods 
Materials 
Dextran (Dex) of MW 67500 was purchased from 
Pharmacosmos (Holbaek, Danemark). Dextran was 
dried in a vacuum oven for 24 h at 50 °C before use. 
All chemicals were used without further purification. 
Acetic anhydride, butyric anhydride, propionic 
anhydride, dextranase (EC 3.2.l.l1) from Penicillium, 
ammonium acetate, sodium azide, sodium potassium 
tartrate, phenol, 3,5-dinitrosalicylic acid, sodium 
sulfite, dimethyl sulfoxide (DMSO), ethyl acetate, 
chloroform, ethanol, methanol, tetrahydrofuran, 
acetone, 2-propanol, dichloromethane, 4-
(dimethylamino) pyridine (DMAP) and triethyl citrate 
were purchased from Sigma-Aldrich Chemical 
Company (Saint Quentin Fallavier, France). 
Theophylline monohydrate was obtained from Cooper 
Rhone (Melun, France). Eudragit® RS 30D was 
obtained from SPCI (St-Denis La Plaine, France). 
 
Synthesis of different dextran esters  
The general synthesis of dextran esters is shown in 
Figure.1. 10 g of dry dextran and 4-Dimethylamino 
pyridine (DMAP) 10% w/w were dissolved in dimethyl 
sulfoxide (DMSO), in a 500 ml two-neck round-
bottomed flask equipped with a stirrer, a condenser and 
a drying tube, and heated to 80 °C. The mixture was 
stirred until it was completely dissolved. Then, the 
required amount of anhydrides acid are slowly added 
drop  by  drop,  and   the   mixture   was   stirred   for  a 
determined period as shown in Table 1, then cooled 
down at room temperature. The obtained dextran esters 
were precipitated in 1000 ml of distilled water and 
filtrated. Then, the precipitate was dissolved into 300 
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ml ethyl acetate, washed three times with distilled 
water, two times with a saturated solution of sodium 
bicarbonate, two times with a saturated solution of 
sodium chloride, and finally two times with distilled 
water, respectively. Then, after evaporation of the 
solvent, the residue was dissolved in a small amount of 
methanol. Finally, the product was isolated by 
precipitation into 1000 ml of distilled water and 
filtrated. The precipitated polymer was dried at 50 C° 
under vacuum during 24 hours. 
 
Table 1: The degree of substitution (DS), the esterification conditions, and the yields of dextran esters 
 
Dextran esters 
 
DSth 
 
DSCal 
 
Volume of 
anhydride acid 
(ml) 
 
Volume of 
DMSO (ml) 
 
Time  of 
reaction  (h) 
 
Yield ( % ) 
3 3.02  30.2   80 4 94.43 
2 1.98 20.1   80 4 92.16 Dextran butyrate 
1 0.98 10.07  80 4 90.12 
3 2.97 24.1  80 4 93.54 
2 1.92 16.1  80 4 92.23 Dextran propionate 
1 0.97 8.03  80 4 90.01 
3 2.93 17.9  200(1) 12(2) 92.13 
2 1.91 11.9  200(1) 12(2) 91.83 Dextran acetate 
1 0.96 5.97  200(1) 12(2) 55.05 
 
Characterization and solubility 
The chemical structure of dextran and the different 
dextran esters were all characterized by FT-IR (Nicolet 
380- Thermo electron, USA), and 1H NMR, 13C NMR 
(Burker Avance PDX300 MHz spectrometer, 
Karlsruhe, Germany). For FT-IR characterization all 
samples were dried into a vacuum oven for at least 24 h 
before analysis. For 1H NMR and 13C NMR the 
samples were dissolved in deuterated DMSO-d6 or 
CDCl3 (both were obtained from Euriso-top, Gif-sur- 
Yvette, France). Chemical shifts (δ) are reported in 
parts per million. For central lines of internal 
references, DMSO-d6 (δ = 2.50) and CDCl3 (δ = 7.24) 
were used. The degree of substitution (DS) was 
estimated from the 1H NMR spectras [13,14]. 
The solubilities of the different dextran esters were 
determined by immersing 20 mg of each sample into a 
solvent for 24 h [15] followed by a filtration and a 
drying of the non soluble fraction. 
 
Enzymatic degradation of different Dextran esters 
30 mg of different dextran esters were incubated in 30 
ml   of   ammonium   acetate   buffer  (5  mM,  pH  5.5)  
 
 
containing 0.02% (w/v) of sodium azide, with three 
concentrations of dextranase (0.5, 5 and 10 U/ml) 
respectively, at 37 °C. The enzyme solution was 
prepared just before use. Periodically, samples of 2 ml 
were taken at different times (2, 6, 24 and 48 h), and 
heated at 95 °C for 10 min to inactivate the enzyme. 
The concentration of reducing oligosaccharides was 
determined as described by Franssen et al. [16,17]. 
Typically, 200 μl of sodium sulfite solution (30 mg/ml) 
and 3 ml of Sumner reagent (0.2 g/ml of sodium 
potassium tartrate, 10 mg/ml of dinitrosalicylic acid, 10 
mg/ml of sodium hydroxide and 2 mg/ml of phenol) 
were added to a sample of 2 ml and were incubated for 
15 min at 95 °C. After cooling to room temperature, the 
absorbance was measured at 620 nm and the 
concentration of reducing oligosaccharides was 
calculated using glucose solutions as references. Each 
experiment was performed in triplicate and the results 
were in agreement within ±3% standard error. 
 
Preparation of free films 
A 10% (w/v) solution of Eudragit® RS 30 D (ERL) 
was prepared in distilled water, and then a fixed 
amount of triethyl citrate (20% to the total polymer 
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content) was added as plasticizer. Required amount of 
dextran acetate (DS1) powder was dissolved in distilled 
water. Dextran acetate solution was gently added to 
Eudragit® RS 30 D solution with continuous stirring. 
The ratios of dextran acetate to Eudragit® RS 30 D 
content were 0, 10, 20 and 30% (w/w) [18]. Identical 
volumes from the resulted suspension were transferred 
to Teflon plates and dried into a ventilated hood at 
temperature ambient for 48 h for complete drying. The 
integrity of the films was checked visually and the film 
thickness was measured at five different places by 
using a micrometer (Käfer, Germany). Free films were 
stored in a desiccator with 50% RH obtained by a 
saturated solution of magnesium nitrate hexahydrate at 
room temperature until use. 
 
Permeability test 
Isolated films of the polymers were mounted between 
the donor and the acceptor compartments of a side-by-
side diffusion cell (Grown Glass Co., Inc., Somerville, 
New Jersey, USA) having a diffusion area of 3.46 cm2. 
The temperature of the cells was kept at 37 ± 0.5 ºC 
throughout the experiments by continuous circulating 
of water and each compartment was stirred 
continuously with a magnetic stirrer. Different 
experimental conditions were set up to examine the 
permeability of drugs through the polymer films. For 
theophylline, used as a hydrophilic model drug, the 
initial concentration of these one in the donor 
compartment was 3.0 mg/ml. To achieve the sink 
conditions for permeability experiments, nearly 
saturated concentration of theophylline was poured into 
the donor compartment. The donor and acceptor 
compartments were both composed of simulated gastric 
fluid (SGF) without pepsin, simulated intestinal fluid 
(SIF) without pancreatin with pH 6.8 (USP XXVIII, 
2005) and simulated colonic fluid (SCF, 0.05 M 
phosphate buffer, pH 6.4) added with 0.5 U/ml of 
dextranase respectively. All of the permeability 
experiments were carried out for 3 h. At predetermined 
time intervals, samples of 10 ml were taken from the 
receptor cells and replaced with fresh medium. The 
contents of the acceptor cells were assayed 
spectrophotometrically for theophylline at 272 nm. 
Each permeation experiment was repeated three times 
and the cumulative amount of drug permeated and 
corrected for the acceptor sample replacement was 
plotted against time. 
Applying Fick's first law of diffusion in sink 
conditions, the permeation rate of drug was defined as: 
 
d
d PSC
h
DSKC ==
t
M
d
d
                                 (1) 
 
Where M, was the amount of drug diffused (mg) at 
time t;  D, the diffusion coefficient; S, the effective 
diffusion area (cm2); Cd, the concentration of drug in 
the donor cell; h, the thickness of membrane; and P, 
was the permeability (cm/s). Then, the permeability 
was obtained by the following equation: 
 
dSC
SlopeP =                                                      (2) 
 
Where the slope was obtained from the plot of the 
amount of drug permeated versus time [19]. 
 
Results and discussion 
Synthesis and characterization of different dextran 
esters 
A series of different dextran esters, acetate, propionate 
and butyrate, with various degrees of substitution (DS: 
1.0, 2.0 and 3.0) were synthesized by esterification 
under anhydrous conditions (Fang et al., 1999).  
Figure 1 gives the general scheme of the esterification 
reaction, and the mechanism of reaction [20]. Dextran 
reacted with acid anhydride in DMSO in presence of 4-
DMAP used as catalyst at 80 °C [21-23]. All or some 
of the hydroxyl groups of dextran were replaced by 
carboxylic groups to give dextran esters (acetate, 
propionate and butyrate). 
The structure of the different dextran esters were 
confirmed by FT-IR, 1H NMR and 13C NMR 
spectroscopies. Figure 2 shows the FTIR spectras of 
the dextran and the different dextran esters. By 
comparing the different FTIR spectras of dextran 
butyrate, we can show a decrease in the O-H band 
(3340 cm-1) and an increase in the three major ester 
bands [ the C=O band (1740 cm-1 ), the C-O band 
(1250 cm-1 ), and the C-CH3 band (1350 cm-1) ], 
providing evidence of esterification as reported by Sun 
et al. [24]. Same results were observed for dextran 
propionate and dextran acetate. 
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Figure 1. General scheme of the synthesis dextran 
esters (a) Mechanism of esterification reaction (b) 
General reaction. 
The chemical structures of the different dextran esters 
were also examined by 1H NMR spectroscopy. The 
characteristic resonance peaks corresponding to the 
protons in methylene groups and other five methanol 
groups of dextran can be observed at 3.4- 4 ppm and 
4.9 ppm. In addition, the signals of protons in dextran 
butyrate appear in the spectrum at 0.92 ppm (-CH2-
CH2-CH3), 1.6 ppm (-CH2-CH2-CH3), and 2.3 ppm (-
CH2-CH2-CH3), the signals of protons in dextran 
propionate appear at 1.08 ppm (-CH2- CH3), and 2.23 
ppm (-CH2- CH3) and the signals of protons in dextran 
acetate appear at 1.9 ppm (-CH3). For the 13C NMR 
spectra, the resonance peaks of the six carbons in 
dextran can be observed at 65.6- 97.7 ppm, the 
resonance peaks corresponding to dextran butyrate 
appear at 13.5 ppm (-CH2-CH2-CH3), 18.8 ppm (-CH2-
CH2-CH3), 35.8 ppm (-CH2-CH2-CH3) and 172.2 ppm 
(carbonyl croups C=O), for dextran propionate appear 
at 9.0 ppm (-CH2-CH3), 27.3 (-CH2-CH3) and 173.3 
ppm (carbonyl croups C=O), and for dextran acetate 
appear at 20.9 ppm (-CH3) and169.8 ppm (carbonyl 
croups C=O) as reported by Wang et al. [25]. 
 
Figure 2. FTIR spectra of dextran butyrate DS.3 
(a), dextran butyrate DS.2 (b), dextran butyrate 
DS.1 (c) and dextran (d). 
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The DS of each dextran esters was calculated as the 
following equation: 
ny
xDS 7=                                                           (3) 
Where x corresponds to the integrated areas of all the 
protons from the ester group, y corresponds to the 
integrated areas of all dextran protons and n 
corresponds to the number of hydrogen atoms in each 
ester group. 
The solubilities of the different dextran esters into 
several organic solvents were examined and the results 
are reported in Table 2. As shown in Table 2, the 
solubilities of the different dextran esters in organic 
solvents are strongly dependent on the degree of 
substitution (DS) and on the type of the groups which 
are attached. By increasing the substitution degree and 
the length of the chains attached onto the dextran unit, 
the solubility of dextran esters can be improved into 
non polar solvents while the solubility into water is 
greatly reduced. 
 
Table 2: Solubilities of the different dextran esters in various solvents 
 
Polymer Water Chloroform THF Ethyl acetate Acetone 2-Propanol Methanol DCM 
Dextran Butyrate DS.3 I S S S S PS I S 
Dextran Butyrate DS.2 I S S S S S S S 
Dextran Butyrate DS.1 I I S I I I S I 
Dextran Propionate DS.3 I S S S S I PS S 
Dextran Propionate DS.2 I S S S S S S S 
Dextran Propionate DS.1 PS S S I I I S I 
Dextran Acetate DS.3 I PS PS I I I PS S 
Dextran Acetate DS.2 I PS I I I I S PS 
Dextran Acetate DS.1 S I I I I I S I 
S (soluble), I (insoluble). PS (particularly soluble), THF: Tetrahydrofuran; DCM: dichloromethane
The behavior of the two highly esterified dextran 
having a DS 2 and 3 differs strongly from esterified 
dextran having a DS1, allowing to conclude that the 
solubilities of dextran esters with a DS equal to 2 or 3 
are strongly different than the dextran slightly 
substituted. 
Enzymatic degradation of different dextran esters 
The in vitro enzymatic degradation of different dextran 
esters was evaluated onto three concentrations of 
dextranase (Figure 3 a, b, c). As well described by 
several authors, the degradability of dextran derivatives 
by dextranase is significantly affected by the type and 
the extent of chemical modification [26,27] and the 
degree of substitution DS of dextran molecules [28]. 
Furthermore, the dextran esters slightly substituted 
(DS=1) by small chain of fatty acids, i.e. an acetate 
group, are degradable by the dextranase, this fact being 
more and more important by increasing the 
concentration of dextranase. 
 
 
(a) 
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Figure 3. Enzymatic degradation of different 
dextran esters into different concentrations of 
dextranase, (a) 0.5 U/ml, (b) 5 U/ml and (c) 10 U/ml. 
 
The study of the enzymatic degradation of the different 
dextran esters allowed us to conclude that the esterified 
dextrans degraded more rapidly as the degree of 
dextran substitution decreased, as the length of the 
attached group decreased and as the dextranase 
concentration increased. This enzymatic degradation 
study allowed us also to show that a too high 
substitution degree of dextran reached to a modified 
polysaccharide which didn’t show any degradability in 
the concentration of dextranase used. 
This fact can be explained by considering the attacking 
mechanism of dextranase, which needs four successive 
α-1,6- linked glucose units to allow the degradation of 
the dextran backbone as suggested by Bauer & 
Kesselhut [29]. 
 
Permeability test 
For the reasons explained above in the section 3.2., we 
prepared films constituted of dextran acetate DS.1, in 
combination with Eudragit® RS 30D as sustained 
release matrix from aqueous suspension. The obtained 
data of the permeability studies of theophylline in 
different media are shown in Figure 4 and table 3. As it 
can be seen, the permeability of the drug through the 
different free films increased with an increase of the 
ratio of the dextran acetate DS.1 in the film. In 
addition, these films showed a high permeability in 
SCF medium for all of the formulations compared to 
the results obtained from films constituted only of 
Eudragit® RS 30D. 
(b) 
 (c) 
 
(a) 
 
(b) 
 
(c) 
 
Figure 4. Permeability profiles of theophylline 
through free films constituted of Eudragit RS 30D - 
Dextran acetate (DS.1), (a) in SGF, (b) in SIF, and 
(c) in SCF. Error bars indicate S.D. (n = 3).  
 
 
Table 3: Permeabilities of theophylline through different free films (date represent mean ± S.D.; n =3) 
 
                                                 P Theo ( x10-5 cm/s) 
Formulation 
LGS LIS LCS LCS + Dextranase 0.5 U/ml 
ERS 100% 1.266 ± 0.145 0.3753 ± 0.024 0.310 ± 0.034 - 
ERS: Dex.Acet (DS.1) 
(90:10) 1.990 ± 0.045 0.510 ± 0.270 0.552  ± 0.047 0.546  ± 0.046 
ERS: Dex.Acet (DS.1) 
(80:20) 6.006 ± 0.238 3.048 ± 0.179 14.954  ± 0.260 14.411  ± 0.416 
ERS: Dex.Acet (DS.1) 
(70:30) 13.442 ± 0.378 13.656 ± 0.401 24.320  ± 0.332 21.566 ± 0.406 
 
Also, as shown in Figure 5, we found little difference 
for the permeability of theophylline in SCF in presence 
or in absence of dextranase. These results can be 
explained by two reasons. The first one could be 
attributed to the too low concentration of dextranase to 
observe a difference between the two experiments and 
the second one could be attributable to the difficulty of 
the dextranase to reach the dextran acetate due to the 
presence of the non degradable, non swollen and 
undissolved Eudragit® RS 30D.  
 
 
 
Figure 5. Permeability profiles of theophylline 
through free films constituted of Eudragit RS 30D - 
Dextran acetate (DS.1) in SCF with 0.5 U/ml of 
dextranase. Error bars indicate S.D. (n = 3). 
The use, in the future, of polymers like cellulose 
derivatives which are able to swell instead of Eudragit 
RS 30D should allow the enzymes to degrade the 
dextran and then to increase the release of the drug. 
Formulations containing Eudragit® RS 30D and 
dextran acetate, showed a higher permeability in SGF 
than in SIF that may be explained by the difference 
between the solubility of theophylline in acidic and in 
neutral pH which is a little lower in the latter pH. Such 
results should lead also, in the future, in adding an 
external additional enteric coating to the dosage forms 
(powders, tablets, capsules) in order to avoid any 
premature release of drug into the stomach. 
 
Conclusion 
In his study, we showed that new modified 
polysaccharides consisting of esterified dextrans with 
acid anhydrides (acetic anhydride, propionic anhydride, 
butyric anhydride) with three degrees of substitution 
can be considered as promising carriers for site specific 
drug delivery to the colon. 
The results of this study indicate that some dextran 
esters i.e. dextran acetate can be enzymatically 
degraded whereas others more highly substituted with 
longer lateral chains didn’t show any enzymatic 
degradability. The degradable modified dextans should 
be promising materials for coatings or as matrix system 
to formulate oral drug dosage forms (tablets, capsules, 
powders and mini granules) as carriers for site specific 
drug delivery to the colon. 
Moreover, the combination of these dextran esters with 
polymethacrylate could be suitable to protect a drug 
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from higher regions of the gastro intestinal tract and to 
ensure drug release into the colon. 
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